Dr Reddys launches generic version of Cubicin to treat skin infections
The company has launched its product Daptomycin, which is a generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
New Delhi: Dr Reddy's Laboratories on Wednesday said it has launched Daptomycin for injection, used for treating complicated skin infections, in the US market.
The company has launched its product, which is a generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.
According to IQVIA Health, the Cubicin for injection (daptomycin for injection) brand and generics had sales of around USD 640.8 million for the most recent 12 months ending in March 2019.
Dr Reddy’s Lab was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad.
Dr Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.